US4523271090 - Common Stock
96.54 +1.89 (+2%)
After market: 96.52 -0.02 (-0.02%)
NASDAQ:ILMN (11/28/2023, 7:10:04 PM)After market: 96.52 -0.02 (-0.02%)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company is headquartered in San Diego, California and currently employs 11,500 full-time employees. The company went IPO on 2000-06-28. The firm operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.
5200 Illumina Way
San Diego CALIFORNIA 92122
CEO: Francis A. deSouza
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Illumina, Inc. ("Illumina" or the "Company") (NASDAQ: ILMN). Such investors are...
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Illumina (ILMN) has reportedly been contacted by parties interested in buying or investing it its Grail cancer test detection unit. Read more here.
/PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in...
Here you can normally see the latest stock twits on ILMN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.